The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Prof. Leif Håkansson

Prof. Leif Hakansson is the Chairman of the CDDF Board of Directors.

He is currently Associate Professor at the University of Lund, Sweden, the Head of the Division of Clinical Tumour Immunology and Consultant in Oncology at University Hospital of Linkoping in Sweden.

He has published approximately 70 peer-reviewed articles and given approximately 40 congress presentations on these and other topics. He is a reviewer for several international scientific journals. He was the secretary and vice chairman of the Biological Development Group (BTDG) of the EORTC.

Prof Hakansson holds two international patents on predictive tests for immunotherapy of cancer.

Research Interest

Prof Hakansson’s research interest is in the development of biological therapeutics in cancer, especially in developing trial strategies / logistics for early clinical trials based on prediction of responders, monitoring therapeutic strategies in order to enable optimisation of the therapeutic efficacy.

Areas of particular research interest include:

  • immunomodulators
  • vaccines
  • cytokines
  • therapeutic antibodies
  • angiogenesis inhibitors
  • signal transduction inhibitors

Contact Prof. Leif Håkansson

Cancer Drug Development Forum
c/o BLSI
Clos Chapelle-aux-Champs 30
1200 Brussels, Belgium
Tel: +32 2 880 62 70

Legal address
c/o Deloitte Tirol
Wirtschaftsprüfungs GmbH,
Wilhelm-Greil-Str. 15,
6020 Innsbruck, Austria